Altimmune (ALT) will host an investor webcast on Thursday, June 26, 2025 at 8:30 am E.T. to present topline 24 week data from its IMPACT Phase 2b trial evaluating pemvidutide in the treatment of patients with metabolic dysfunction-associated steatohepatitis.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Nucor, Charter, Senseonics, Shake Shack, Altimmune: Trending by Analysts
- Altimmune management to meet virtually with B. Riley
- Altimmune announces initiation of RECLAIM Phase 2 trial on pemvidutide
- Altimmune’s Earnings Call: NASH Trial & Financial Moves
- Altimmune’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating